Last reviewed · How we verify
Paclitaxel + bevacizumab therapy
Paclitaxel stabilizes microtubules to inhibit cell division, while bevacizumab blocks VEGF to prevent tumor angiogenesis, combining chemotherapy with anti-angiogenic effects.
Paclitaxel stabilizes microtubules to inhibit cell division, while bevacizumab blocks VEGF to prevent tumor angiogenesis, combining chemotherapy with anti-angiogenic effects. Used for Metastatic or recurrent ovarian cancer, Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | Paclitaxel + bevacizumab therapy |
|---|---|
| Sponsor | Japanese Foundation for Cancer Research |
| Drug class | Chemotherapy + monoclonal antibody combination |
| Target | β-tubulin (paclitaxel); VEGF (bevacizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel is a taxane chemotherapy agent that binds to β-tubulin and prevents microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor (VEGF) that inhibits tumor neovascularization and reduces blood supply to tumors. The combination leverages direct cytotoxic effects with anti-angiogenic activity to enhance overall anti-tumor efficacy.
Approved indications
- Metastatic or recurrent ovarian cancer
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Hypertension
- Proteinuria
- Nausea/vomiting
- Alopecia
- Bleeding/hemorrhage
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (PHASE3)
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) (PHASE3)
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors (PHASE1)
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (PHASE3)
- PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: